Hypertrophic cardiomyopathy is a common inherited cardiovascular disease with a prevalence ranging from 1:200 to 1:500, considering the subclinical and variable phenotypic expression, familial transmission, and pathogenic mutations. Cardiovascular magnetic resonance (CMR) plays a pivotal role in the diagnosis of HCM. It has been given a class I indication by AHA/ACC if the initial workup with echocardiography is inconclusive or there are other differentials such as infiltrative cardiomyopathy or athlete’s heart. Notably, CMR can help in the risk stratification for sudden cardiac death. Parametric imaging, including T 1 and ECV values, can help differentiate hypertensive heart disease and athlete’s heart from borderline hypertrophic cardiomyopathy patients without salient LGE enhancement patterns.